预约演示
更新于：2025-09-23
Nemonoxacin Malate
苹果酸奈诺沙星
更新于：2025-09-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2016-05-27), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C24H31N3O9 |
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N |
CAS号951163-60-3 |
关联
17
项与 苹果酸奈诺沙星 相关的临床试验CTR20231866
评价苹果酸奈诺沙星胶囊治疗单纯性尿路感染的有效性与安全性的多中心、随机、双盲、左氧氟沙星平行对照的Ⅲ期临床研究
CTR20181341
评价口服苹果酸奈诺沙星（Nemonoxacin）治疗成人社区获得性肺炎患者的有效性和安全性的多中心Ⅳ期临床研究
NCT05133752
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia
100 项与 苹果酸奈诺沙星 相关的临床结果
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的转化医学
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的专利（医药）
登录后查看更多信息
85
项与 苹果酸奈诺沙星 相关的文献（医药）2025-07-01AMERICAN FAMILY PHYSICIAN
Top 20 Research Studies of 2024 for Primary Care Physicians.
Review
作者: Ebell, Mark H ; Grad, Roland
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus. Amoxicillin with or without clavulanate is more effective than placebo for children with symptoms of acute sinusitis. Benzyl benzoate 25% is highly effective for scabies in adolescents and adults. Lactobacillus-containing probiotics reduce the incidence of recurrent urinary tract infections (UTIs) in premenopausal women with frequent UTIs. Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome. For patients with uncomplicated gallstones, conservative management is a reasonable option. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are better than older drugs at improving patient-oriented outcomes for type 2 diabetes. Continuous or intermittent glucose monitoring is minimally effective for control of type 2 diabetes and can be harmful. Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss. Semaglutide is effective for secondary prevention of cardiovascular disease in people with obesity and no diabetes. SGLT-2 inhibitors and GLP-1 receptor agonists decrease cardiovascular death in older adults with type 2 diabetes and heart failure. Beta blockers do not prevent subsequent events after myocardial infarction in patients with preserved ejection fraction. For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates. e-Cigarettes increase abstinence from smoking, but long-term vaping is a consequence for some. Oral naltrexone and acamprosate are safe and effective treatments for alcohol use disorder. Cognitive behavior therapy can reduce fatigue attributed to long COVID. New monoclonal antibodies for Alzheimer disease are harmful, expensive, and minimally effective. Clinicians may choose to deliver bad news in person or by telephone, using their judgment or patient preference to decide which is best for the patient.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2024-09-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Metagenomic next-generation sequencing assistance in identifying Mycobacterium iranicum pulmonary infection: A case report
Article
作者: Wang, Linlin ; Song, Yuanlin ; Xu, Li ; Tong, Lin
Nontuberculous mycobacteria (NTM) are important opportunistic pathogens in humans, mostly affecting the lungs, and potentially causing progressive disease in individuals with underlying diseases. The prevalence of NTM infections is increasing worldwide. However, Mycobacterium iranicum (M. iranicum) infections are less common. Here we report a 65-year-old female who developed pneumonia caused by Mycobacterium iranicum, which was detected in bronchoalveolar lavage fluid (BALF) through metagenomic next-generation sequencing (mNGS). The patient was treated with moxifloxacin, doxycycline, and sulfamethoxazole/trimethoprim. Symptoms were relieved and lung abnormalities were shown to be partially absorbed on the follow-up chest computed tomography (CT) scans. As we know, this is the first case of Mycobacterium iranicum pulmonary infection identified by mNGS in BALF.
100 项与 苹果酸奈诺沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性肺炎 | 中国 | 2016-05-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 感染 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 泌尿道感染 | 临床3期 | 中国 | 2023-08-29 | |
| 细菌性肺炎 | 临床3期 | 俄罗斯 | 2016-05-04 | |
| 糖尿病足感染 | 临床2期 | 美国 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 南非 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 中国台湾 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 泰国 | 2008-06-01 | |
| 功能障碍 | 临床1期 | 中国 | 2017-04-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 342 | Placebo (100 ml)+Nemonoxacin (Nemonoxacin) | 觸顧窪範鬱齋膚壓簾構: Difference in percentage = 6.1 (95% CI, -0.7 ~ 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 ~ 4.29), P-Value = 0.499 更多 | - | 2023-02-16 | ||
Placebo (250 ml)+Tavanic (Tavanic®) | |||||||
临床1期 | 10 | (Moderate Hepatic Impairment Group) | 鏇顧築蓋鏇選鹽淵繭範(壓選夢衊淵餘鹽鬱醖簾) = 壓憲簾鬱簾夢繭鏇積膚 製範糧齋簾觸構鹽壓壓 (壓夢獵醖鑰醖顧鹹淵觸, (17.30)) | - | 2019-03-01 | ||
(Healthy Control Group) | 鏇顧築蓋鏇選鹽淵繭範(壓選夢衊淵餘鹽鬱醖簾) = 醖鏇淵醖窪積淵齋遞範 製範糧齋簾觸構鹽壓壓 (壓夢獵醖鑰醖顧鹹淵觸, (10.16)) | ||||||
临床3期 | 527 | 範廠觸襯窪獵簾鏇簾衊(糧淵網範鑰鹹鬱獵窪鏇) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) 願繭廠糧構遞製觸淵鹽 (築夢餘願憲艱夢夢繭簾 ) | 积极 | 2019-02-01 | |||
临床2期 | 192 | 淵夢製衊淵憲糧顧壓蓋(蓋願網築鑰顧壓衊壓壓) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes 窪餘醖淵衊淵製觸願觸 (餘鏇艱衊繭範範鹽築襯 ) 更多 | 积极 | 2017-12-01 | |||
临床2期 | - | 207 | 餘願餘廠窪遞網鑰範淵(鑰蓋壓積鑰觸窪鹽齋壓) = 顧蓋製遞鹹鏇膚鬱遞淵 廠鏇顧壓醖蓋膚遞壓網 (窪鏇願觸獵壓襯餘鏇餘 ) 更多 | - | 2015-03-01 | ||
餘願餘廠窪遞網鑰範淵(鑰蓋壓積鑰觸窪鹽齋壓) = 範衊夢願憲鑰顧壓繭選 廠鏇顧壓醖蓋膚遞壓網 (窪鏇願觸獵壓襯餘鏇餘 ) 更多 | |||||||
临床2期 | 207 | (Nemonoxacin 500 mg) | 鹽繭壓艱築範遞醖鑰築 = 憲壓餘糧網鏇鬱願壓廠 淵夢觸鹽襯廠遞獵餘糧 (網積顧觸獵選膚淵夢淵, 夢積顧艱鹽鏇鬱獵簾觸 ~ 構蓋衊鏇願醖窪壓觸齋) 更多 | - | 2015-02-18 | ||
(Nemonoxacin 650 mg) | 鹽繭壓艱築範遞醖鑰築 = 簾簾獵獵顧襯廠襯願淵 淵夢觸鹽襯廠遞獵餘糧 (網積顧觸獵選膚淵夢淵, 窪獵醖構壓艱艱夢壓積 ~ 廠鑰廠鹽餘夢鬱鏇廠顧) 更多 | ||||||
临床2期 | - | 92 | 選構獵齋築鏇觸選餘願(獵築願齋鹹廠簾選範壓) = 夢獵繭鏇淵醖鑰壓夢淵 糧膚積觸襯繭窪鹽餘糧 (積遞獵糧鹹遞窪觸繭鑰 ) 更多 | - | 2014-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用